Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

Open access
Wick, Wolfgang, Meisner, Christoph, Hentschel, Bettina, Platten, Michael, Schilling, Alissa, Wiestler, Benedikt, Sabel, Michael C., Koeppen, Susanne, Ketter, Ralf, Weiler, Markus, Tabatabai, Ghazaleh, von Deimling, Andreas, Gramatzki, Dorothee, Westphal, Manfred, Schackert, Gabriele, Loeffler, Markus, Simon, Matthias, Reifenberger, Guido, Weller, Michael · 2013 · Neurology

Abstract

OBJECTIVE: To explore whether the isocitrate dehydrogenase 1 (IDH1) or 1p/19q status determines the prognostic vs predictive role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in the Neuro-Oncology Working Group of the German Cancer Society (NOA)-04 trial anaplastic glioma biomarker cohort. METHODS: Patients (n = 183) of the NOA-04 trial with known MGMT and IDH1 status were analyzed for interdependency of the prognostic vs predictive role of MGMT promoter methylation from IDH1 or 1p/19q status and treatment, using progression-free survival (PFS) as an endpoint. An independent validation cohort of the German Glioma Network (n = 75) and the NOA-08 trial (n = 34) served as a confirmation cohort. RESULTS: In tumors with IDH1 mutation, MGMT promoter methylation was associated with prolonged PFS with chemotherapy ± radiotherapy (RT) or RT-only groups, and is thus prognostic. In tumors without IDH1 mutation, MGMT promoter methylation was associated with increased PFS in patients treated with chemotherapy, but not in those who received RT alone as the first-line treatment, and is thus chemotherapy-predictive. In contrast, 1p/19q codeletions showed no such association with the prognostic vs predictive value of MGMT. CONCLUSIONS: MGMT promoter methylation is a predictive biomarker for benefit from alkylating agent chemotherapy in patients with IDH1-wild-type, but not IDH1-mutant, malignant gliomas of World Health Organization grades III/IV. Combined IDH1/MGMT assessment may help to individualize clinical decision-making in neuro-oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3182a95680

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 234

Metadata

Authors
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M. C., Koeppen, S., Ketter, R., Weiler, M., Tabatabai, G., von Deimling, A., Gramatzki, D., Westphal, M., Schackert, G., Loeffler, M., Simon, M., Reifenberger, G., & Weller, M.
Venue
Neurology
Published
2013-10-22
Volume
81
Issue
17
Pages
1515-1522
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2141713919
Cited by
234
References
5
FWCI
12.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. https://app.cochat.ai/papers/10.1212/wnl.0b013e3182a95680
The paper
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M. C., Koeppen, S., Ketter, R., Weiler, M., Tabatabai, G., von Deimling, A., Gramatzki, D., Westphal, M., Schackert, G., Loeffler, M., Simon, M., Reifenberger, G., & Weller, M. (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. https://doi.org/10.1212/wnl.0b013e3182a95680

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.